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Acute myeloid leukemia (AML) is driven by leukemia stem cells (LSCs) that resist 41 
conventional chemotherapy and are the major cause of relapse1,2. Hypomethylating agents 42 
(HMA) are the standard of care in the treatment of elderly or unfit AML patients, but 43 
responses are modest and not durable3–5. Here, we demonstrate that LSCs upregulate the 44 
tumor necrosis factor (TNF) family ligand CD70 in response to HMA treatment resulting in 45 
increased CD70/CD27-signaling. Blocking CD70/CD27-signaling and targeting CD70-46 
expressing LSCs with cusatuzumab, a human αCD70 monoclonal antibody (mAb) with 47 
enhanced antibody-dependent cellular cytotoxicity activity (ADCC), eliminated LSCs in vitro 48 
and in xenotransplantation experiments. Based on these pre-clinical results, we performed a 49 
phase 1/2 trial in previously untreated elderly AML patients with a single dose of 50 
cusatuzumab monotherapy followed by a combination therapy with the HMA azacitidine 51 
(NCT03030612). Here, we report results from the phase 1 dose escalation part of the clinical 52 
trial. Hematologic responses in the 12 patients enrolled included 8 CR, 2 CRi, and 2 PR with 53 
4 patients achieving MRD negativity by flow cytometry at <10-3.  Median time to response 54 
was 3.3 months. Median progression free survival (PFS) was not reached yet at the time of the 55 
data cut-off. No dose-limiting toxicities (DLTs) were reported and the maximum tolerated 56 
dose (MTD) of cusatuzumab was not reached. Importantly, cusatuzumab treatment 57 
significantly reduced LSCs and triggered gene signatures related to myeloid differentiation 58 
and apoptosis. 59 
  60 
The TNF receptor ligand CD70 is transiently up-regulated on immune cells upon activation 61 
but not expressed in normal tissue and on hematopoietic cells during homeostasis6,7. 62 
However, CD70 is expressed on various solid tumors and on Non-Hodgkin lymphomas and 63 
its expression correlates with poor survival8–10. We recently demonstrated that CD34+ AML 64 
cells (progenitors and LSCs) consistently express CD70 as well as its receptor CD27 and that 65 




sensitive to methylation11,12. To analyze whether HMA treatment results in up-regulation of 67 
CD70 on LSCs, BM lin-CD90-CD34+CD38- LSCs1 from newly diagnosed AML patients 68 
(Supplementary Table 1, Supplementary Fig. 1a) were cultured in the presence and absence of 69 
a pharmacological concentration of decitabine (D) or azacitidine (A)13,14. HMA treatment 70 
reduced LSC numbers by approximately 45%, independent of the risk category15 71 
(Supplementary Fig. 1b). The HMA-resistant LSCs had a significantly higher expression of 72 
CD70 than vehicle-treated control samples (Figs. 1a, Supplementary Figs. 1c-d). In contrast, 73 
HMA treatment reduced the numbers of lin-CD90-CD34+CD38+ blasts and lin-74 
CD90+CD34+CD38- hematopoietic stem cells (HSCs) from normal control BM (ctrl.) without 75 
increasing CD70 expression (Figs. 1a, Supplementary Figs. 1b, d, e). Similarly, HMA 76 
treatment did not affect CD70 expression on NK cells and DCs derived from peripheral blood 77 
(PB) of healthy donors, two cell populations with reported transient CD70 expression during 78 
activation (Supplementary Figs. 1f, g)7. 79 
HMA treatment increased CD70 expression on LSCs but not lymphocytes in PB of AML 80 
patients (Fig. 1b, c, Supplementary Fig. 1h). CD70 expression on AML LSCs negatively 81 
correlated with the degree of methylation of the CD70 promoter (Fig. 1d). In contrast, the 82 
CD70 promoter of HSCs showed only a moderate degree of methylation (Supplementary Fig. 83 
1i). Treatment of lin-CD90-CD34+AML cells in vitro with HMA significantly reduced the 84 
methylation of the CD70 promotor (Fig. 1e). The CD70 promotor contains binding sites for 85 
various transcription factors such as specificity protein 1 (SP-1)16. SP-1 expression was up-86 
regulated in lin-CD90-CD34+AML cells after treatment with HMAs, whereas miR-29b, a 87 
negative regulator of SP-117, was expressed at lower levels (Figs. 1f, g). Overall these data 88 
indicate that HMAs induce CD70 expression in leukemia stem/progenitor cells (LSPCs) by 89 
demethylation of the CD70 promotor and by down-regulating miR-29b levels resulting in the 90 




Ligation of CD27 on LSCs by CD70 induces Wnt-pathway activation, symmetric cell division 92 
and thereby maintains and expands LSCs11. To determine the functional relevance of the 93 
HMA-induced up-regulation of CD70 and increased CD70/CD27-signaling, we cultured 94 
LSCs in the presence of either a blocking αCD70 mAb (clone: 41D12-D)18,19 or HMA alone 95 
or in combination (αCD70/HMA). 41D12-D is an αCD70 mAb with deficiency in effector 96 
function due to E233P/L234V/L235A amino acid substitutions in the CH2 region18,19 and has 97 
the same binding domain as cusatuzumab. CD27 is shed from the cell surface after ligation 98 
with CD70 resulting in the release of soluble CD27 (sCD27)7. Treatment of LSCs with 99 
αCD70 mAb in vitro significantly reduced sCD27 levels suggesting that the CD70/CD27 100 
interaction is efficiently blocked (Fig. 1h). HMA treatment of LSCs strongly increased sCD27 101 
levels indicating enhanced CD70/CD27-signaling. This increased CD27 ligation and release 102 
of sCD27 was completely blocked by adding αCD70 mAb (Fig. 1h). αCD70 treatment 103 
inhibited cell growth without affecting cell viability. In contrast, HMA treatment triggered 104 
cell death of LSCs (Supplementary Figs. 1j, k). Importantly, the αCD70/HMA combination 105 
treatment significantly reduced LSC numbers compared to monotherapy by increasing cell 106 
death (Supplementary Fig. 1j).  107 
As previously reported11, treatment with an αCD70 mAb reduced colony formation and 108 
induced differentiation of LSPCs as indicated by a trend towards increased cell numbers per 109 
colony (Fig. 1i, Supplementary Fig. 1l). The combination treatment synergistically reduced 110 
colony formation capacity compared to monotherapy (Fig. 1i). HMA treatment of LSCs prior 111 
to plating in methylcellulose up-regulated CD70 mRNA expression independent of the 112 
addition of αCD70 mAb (Supplementary Fig. 1m). The impaired colony formation after 113 
combination treatment observed after the first plating was maintained in subsequent re-114 
platings in the absence of αCD70 mAb and HMA (Fig. 1i). These experiments suggest that 115 




HSCs was only affected to a minor extent by HMA treatment but not by the addition of the 117 
αCD70 mAb (Supplementary Fig. 1n) and CD70 mRNA expression in HSCs was not affected 118 
by HMA treatment prior to plating in methylcellulose (Supplementary Fig. 1o). These 119 
experiments indicated that blocking the CD70/CD27 interaction in combination with HMA 120 
treatment synergistically eliminates LSPCs in vitro.  121 
To analyze the therapeutic potential of combining a blocking αCD70 mAb with HMAs in 122 
vivo, we performed patient-derived AML xenograft experiments (PDX)1. After engraftment 123 
of human AML cells, NOD/SCID γc-/-(NSG) mice were randomized to treatment with vehicle 124 
(Veh), αCD70 mAb (41D12-D, 3x10mg/kg over 5 days), decitabine (D, 1.5mg/kg/day) or 125 
αCD70 mAb and decitabine in combination (Supplementary Fig. 2a). Decitabine treatment 126 
induced a significant up-regulation of CD70 on LSCs but not on blasts (Figs. 1j, 127 
Supplementary Fig. 2b-d). Furthermore, sCD27 levels were elevated in sera of PDX AML 128 
mice treated with decitabine compared to controls, indicating that decitabine-induced CD70 129 
expression triggers CD70/CD27-signaling in AML mice in vivo (Fig. 1k). Treatment with the 130 
αCD70 mAb significantly reduced sCD27 levels especially in αCD70/decitabine-treated mice 131 
(Fig. 1k). 132 
αCD70 and decitabine monotherapy significantly reduced leukemic engraftment in BM, 133 
spleen and blood compared to vehicle-treated AML mice (Supplementary Figs. 2e, f, data not 134 
shown).  Importantly, co-treatment synergistically reduced the engraftment of CD45+lin-135 
CD34- and CD45+lin-CD34+ AML cells as well as of CD45+lin-CD34+CD38- LSCs in the BM 136 
(Figs. 1l, m, Supplementary Figs. 2g, h). Similarly, the more primitive CD45RA-expressing 137 
LSCs20 are reduced after combination treatment (Supplementary Fig. 2i). Decitabine 138 
monotherapy had no effect on LSC numbers (Fig. 1m, Supplementary Fig. 2h). BM cells from 139 
αCD70/D-treated mice formed significantly fewer colonies in methylcellulose compared to 140 




by αCD70/D-treatment. Enhanced limiting dilution analysis (ELDA)21 from the BM of 142 
primary PDX AML mice to NSG mice revealed that αCD70/D co-treatment significantly 143 
reduced human AML LSCs in PDX mice compared to either monotherapy as indicated by a 144 
substantial reduction in LSC frequency by a factor of 2.9 and 11 in patients P10 and P25, 145 
respectively (Fig. 1o, Supplementary Table 2). The PDX results indicated that HMA 146 
treatment increased CD70 expression and promoted consecutive CD70/CD27-signaling. The 147 
combination with blocking αCD70 mAb synergistically reduced LSC numbers in vivo. 148 
 149 
Next, we analyzed whether targeting CD70 with the ADCC-enhanced αCD70 mAb 150 
cusatuzumab efficiently reduces LSPCs than the blocking αCD70 mAb (41D12-D). In the 151 
absence of NK cells cusatuzumab demonstrated a similar capacity in reducing colony 152 
formation in vitro as the blocking αCD70 mAb. In the presence of NK cells, cusatuzumab but 153 
not 41D12-D mAb treatment further reduced colony formation (Fig. 2a). In contrast, 154 
cusatuzumab did not affect colony formation of HSCs from normal control BM (Fig. 2b). To 155 
validate our findings in vivo, PDX AML mice were treated either with control mAb, αCD70 156 
mAb (clone: 41D12-D) or cusatuzumab. Cusatuzumab was similarly effective in reducing 157 
leukemia cell engraftment and LSC numbers as the blocking αCD70 mAb in the absence of 158 
NK cells. However, in the presence of NK cells, cusatuzumab further reduced leukemia 159 
engraftment and LSC numbers in BM and spleen (Figs. 2d-e, Supplementary Figs. 3a-c). The 160 
reduction in LSPC numbers in the BM was functionally confirmed by colony forming assays 161 
ex vivo (Fig. 2f).  162 
CD70 up-regulation by HMA may render LSCs even more susceptible to direct cytolytic 163 
interventions. To test this hypothesis, we performed a drug combination study according to 164 
the Chou-Talalay method22. Decitabine increased CD70 expression and in combination with 165 
cusatuzumab in the presence of NK cells synergistically killed CD70-expressing MOLM-13 166 




Next, we treated human LSCs and blasts with cusatuzumab or decitabine monotherapy or in 168 
combination and assessed colony formation.  Although, AML blasts do not upregulate CD70 169 
upon treatment with HMA (Supplementary Fig. 1e), CD70 is expressed on both LSCs- and on 170 
blasts11. Indeed, cusatuzumab/HMA co-treatment in the presence of NK cells effectively 171 
eliminated both, LSCs and blasts, compared to all other treatment groups (Fig. 2g, h). 172 
Decitabine monotherapy quite efficiently eliminated blasts but only marginally reduced LSCs. 173 
Only the combination with cusatuzumab eliminated LSCs. Cusatuzumab treatment uniformly 174 
promoted the expression of myeloid differentiation genes such as SPI1 (PU.1) and CEBPα 175 
and reduced cell viability in average by approximately 85 percent compared to control 176 
treatment (Figs. 2i, j).  177 
These results indicate that a combination of HMA with the ADCC-enhanced αCD70 mAb 178 
cusatuzumab eliminates LSCs synergistically and more efficiently than in combination with 179 
an αCD70-blocking mAb. 180 
 181 
Based on our preclinical data, we designed a phase 1/2 trial to study safety, tolerability and 182 
the efficacy of cusatuzumab as monotherapy and in combination with azacitidine (EudraCT 183 
number 2016-002151-17; see online methods). Untreated AML patients, including de novo, 184 
secondary and therapy-related AML, not fit for intensive chemotherapy were included in the 185 
study. Azacitidine was administered at a standard dose of 75mg/m2 subcutaneously (s.c.) for 186 
seven consecutive days every 28 days. Cusatuzumab was infused at day 3 when CD70 was 187 
upregulated on LSCs by HMA and on day 17 of each treatment cycle. A first infusion of 188 
cusatuzumab at day -14, in the absence of azacitidine, enabled us to study the effect of 189 
cusatuzumab monotherapy (Fig. 3a).  190 
The clinical cut-off for data from the phase 1 part of the study was February 18, 2019 with the 191 




recommended dose for the phase 2 part (RP2D) in combination with azacitidine. Twelve 193 
untreated AML patients with a median age of 75 years (range, 64-84) were enrolled in four 194 
sequential dose cohorts of cusatuzumab (1, 3, 10, or 20mg/kg; 3 patients per dose cohort) in 195 
the dose-escalation part of the trial (Fig. 3a, Supplementary Table 3). Patients had adverse 196 
(n=5), intermediate (n=5) and favorable (n=2) ELN risk features based on genotype and 197 
cytogenetics15. No dose-limiting toxicities (DLTs) were reported and the MTD of 198 
cusatuzumab was not reached.  199 
All 12 patients had at least one treatment-emergent adverse event (TEAE, total of 167 events), 200 
and all 12 patients had at least one grade ≥3 TEAEs (71 events). Nine patients were reported 201 
with drug-related TEAEs (17 events) of which two patients experienced infusion-related 202 
reactions (IRR, six events). Treatment-emergent serious AEs (SAE) were reported for nine 203 
patients (19 events) out of which two were drug-related SAEs reported for one single patient 204 
(Supplementary Tables 4-6). 205 
Hematologic toxicities related to azacitidine were the most frequent TEAE (34 events in 10 206 
patients)3. The only patient with early death succumbed to progression of AML. In addition, 207 
no increase of viral or fungal infections was observed.  208 
Cusatuzumab monotherapy did not affect the numbers of CD4+ and CD8+ T cells in PB, two 209 
cell populations which are known to transiently express CD70 during immune activation7. In 210 
contrast, the CD4+/CD8+ T cells ratio slightly increased after cusatuzumab monotherapy 211 
(Supplementary Fig. 5). Long-term exposure of the patients to the cusatuzumab/azacitidine 212 
combination treatment did not affect normal hematopoiesis as indicated by normal blood 213 
counts and leukocyte differential in the six patients which have been treated for longer than 6 214 
months at the time point of data cut-off February 18th, 2019 (Supplementary Table 7). 215 
In the phase 1 part of the clinical trial, best hematologic response (BR) was complete 216 
remission (CR) in 8 patients, CR with incomplete hematologic recovery (CRi) in 2 patients, 217 




12 patients achieved a CR/CRi. Responses were observed at all dose levels of cusatuzumab 219 
and median time to response was 3.3 months. Importantly, responses were durable with 6 220 
patients still on study treatment at the time of data cut-off and median progression free 221 
survival (PFS) was not reached yet.  Four out of 9 evaluable patients (44%) with CR/CRi 222 
achieved MRD-negativity by flow cytometry in the BM at a threshold of 10-3 (Fig. 3d, 223 
Supplementary Table 8). End of treatment (EOT) was caused by progression in 4 patients, by 224 
referral to allogeneic transplantation in CR in patient C2 and by treatment-related toxicity 225 
(hypertension) in 1 patient.  226 
Importantly, cusatuzumab monotherapy reduced BM blasts in only two weeks in all patients 227 
on average to 32% with three responders (1 CR, 1 CRi and 1 PR) among the 12 patients. The 228 
combination with azacitidine further reduced the BM blast counts by 92% compared to C1D1 229 
(Fig. 3e-f). No correlation between response to cusatuzumab treatment with the numbers and 230 
frequencies of NK cells in peripheral blood at day -14 could be observed (Supplementary Fig. 231 
6).  232 
 233 
CD70 expression was detectable on CD34- AML cells and LSPCs in a majority of patients 234 
(Fig. 4a). To monitor the degree of CD70/CD27 interaction in the patients in vivo, we 235 
assessed sCD27 levels in the sera of patients enrolled in the study at day -14. sCD27 levels 236 
were significantly increased in all AML patients compared to healthy age-matched controls 237 
(HD, Fig. 4b). Cusatuzumab monotherapy significantly reduced sCD27 levels within 14 days 238 
of treatment (Fig. 4b, c). The combination of azacitidine with cusatuzumab further decreased 239 
sCD27 at the time point of BR to levels comparable to HD controls (Fig. 4c, d). 240 
Cusatuzumab monotherapy reduced LSPC numbers by a factor of 3, as assessed by the colony 241 
forming capacity of plated total BM cells (Fig. 4e). ELDA revealed that monotherapy with 242 
cusatuzumab significantly reduced LSC numbers compared to day -14 in all patients analyzed 243 




The in vitro experiments do not allow to unambiguously distinguish between LSPCs and 245 
normal hematopoietic stem/progenitor cells. The most stringent experiment to assess LSC 246 
numbers is to analyze engraftment of titrated numbers of BM cells after transplantation into 247 
sub-lethally irradiated NSG mice (Fig. 4i). ELDA indicated that cusatuzumab monotherapy in 248 
patient C2 reduced the LSC frequency by approximately 47-fold (Fig. 4j, k). These data 249 
suggest that targeting CD70 by cusatuzumab monotherapy reduces LSCs in AML patients. 250 
To address the molecular mechanism of cusatuzumab on AML LSCs, we performed scRNA-251 
sequencing of FACS-purified lin-CD34+ AML cells from patients C8 and C10 at day -14 and 252 
after cusatuzumab monotherapy (C1D1) (Supplementary Figs. 7a-c). Patient C10 harbored 253 
two AML clones which differed in the expression of CD34; the CD34+ clone was purified and 254 
included in the scRNA-sequencing analysis (Supplementary Table 3). To focus on malignant 255 
cells, we took advantage of the molecular mutations identified at diagnosis in patients C8 256 
(DNMT3a) and C10 (ASXL1, EZH2, RUNX1, SH2B3, ZRSR2) using a data crushing 257 
approach separating cells that did or did not express the molecular marker. This approach 258 
identified a frequency of 77% and 74% of malignant AML cells at day -14 and C1D1 for 259 
patient C8, respectively, and 99.9% for patient C10 at both time points. No distinct clusters 260 
could be identified in principal component analysis (PCA) of single cells of patients C8 and 261 
C10 at diagnosis or after cusatuzumab monotherapy suggesting the predominance of a clonal 262 
population with similar cellular states (Supplementary Fig. 7d). We identified 47 and 18 263 
differentially expressed genes after cusatuzumab monotherapy for patients C8 and C10, 264 
respectively (Supplementary Figs. 7e-h, Supplementary Tables 9, 10). Patients C8 and C10 265 
shared 9 differentially expressed genes (7 mRNAs and 2 LncRNAs, Fig. 4l). Gene ontology 266 
analysis of these 9 genes revealed a preferential involvement in TGF-β, AP-1-, MAPK-, 267 
cAMP-, TNF-, MyD88-signaling and induction of pro-inflammatory cytokines all associated 268 




Lastly, we assessed the level of apoptotic lin-CD34+ LSPCs at day -14 and C1D1 in 7 out of 270 
12 patients by Annexin-V staining. After cusatuzumab treatment (C1D1), the frequency of 271 
apoptotic cells was significantly increased compared to day -14 (Fig. 4n).  Collectively, these 272 
data suggest that cusatuzumab treatment triggers differentiation and apoptosis in LSPCs.  273 
 274 
The CD70/CD27 interaction maintains self-renewal of AML LSCs by activating Wnt-275 
signaling and by promoting symmetrical cell division11. Since CD70 is only transiently 276 
expressed on activated lymphocytes but not during homeostasis7, targeting the CD70/CD27 277 
interaction may allow selective elimination of CD70-expressing LSCs. In the present study, 278 
we document CD70 up-regulation and reinforced CD70/CD27-signaling on LSCs in response 279 
to HMA treatment. Increased expression of CD70 offers two therapeutic strategies to 280 
selectively target LSCs. First, blocking the CD70/CD27 interaction reduces 281 
CD27/TNIK/Wnt-signaling and self-renewal of LSCs and induces differentiation11. Secondly, 282 
the unique expression pattern of CD70 allows for direct cytolytic targeting11,23. We explored 283 
both possibilities in vitro and in a limited number of xenotransplantation experiments using an 284 
αCD70 mAb with deficiency in effector function due to E233P/L234V/L235A amino acid 285 
substitutions in the CH2 region18,19 and an ADCC-enhanced version of the same clone 286 
(cusatuzumab)19,24. Both, blocking CD70/CD27-signaling and ADCC-mediated target cell 287 
killing synergistically eliminated LSCs. However, cusatuzumab was clearly superior to the 288 
blocking-only variant of the antibody. Therefore, cusatuzumab was tested in a phase 1/2 trial 289 
together with azacitidine. Within only two weeks, cusatuzumab monotherapy reduced blast 290 
counts in the BM on average to 32% with two patients reaching a CR (1 CR, 1 CRi) and one 291 
patient a PR. In addition, cusatuzumab monotherapy significantly reduced LSCs up to 50-292 
fold.   293 
Overall response rate for the combination of cusatuzumab with azacitidine was 100% (8 CR, 294 




Responses were observed in all dose levels of cusatuzumab. Although this phase 1 study only 296 
included 12 patients, the observed response rate favorably compares with historical data on 297 
HMA monotherapy3,4.  298 
Different novel compounds have been tested in combination with low-dose Ara-C or HMAs 299 
in elderly non-fit AML patients (reviewed in 25). Similar to cusatuzumab, venetoclax 300 
eliminates LSCs, albeit by a different mechanism, i.e. by suppressing oxidative 301 
phosphorylation26.  302 
In conclusion, cusatuzumab monotherapy and in combination with azacitidine is highly active 303 
previously untreated patients with AML unfit for intensive chemotherapy. Cusatuzumab 304 
eliminates CD70-expressing LSCs potentially leading to deep and durable remissions. 305 
Currently ongoing and future clinical phase 2 and 3 studies will further investigate the 306 
potential of cusatuzumab to induce durable responses and deep remissions in combination 307 
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 424 
Figure legends 425 
 426 
Fig. 1: αCD70/decitabine combination therapy eradicates human CD34+CD38- LSCs in 427 
vitro and in vivo. (a) 105 FACS-purified lin-CD90-CD34+CD38- LSCs from BM of newly 428 
diagnosed AML patients and lin-CD90+CD34+CD38- HSCs from normal donor BM (ctrl., 429 
Supplementary Table 1) were cultured in StemSpan SFEM medium in the presence or 430 
absence of 0.5 μM azacitidine (A, P8), decitabine (D, P11) or vehicle (Veh) in duplicates. 431 
Fold change ΔMFI CD70 after HMA treatment (AML is depicted as open symbols, ctrl. as 432 
closed symbols, azacitidine (A) in red and decitabine (D) in blue; n=3 and 16 AML patients 433 




two-sided Student’s t-test (ALL vs ctrl.). (b) Representative FACS plots of CD70 expression 435 
on lin-CD90-CD34+CD38- LSC in the PB of AML patient P22 at diagnosis and after 1 cycle 436 
of azacitidine or decitabine treatment A(7), 75 mg/m2, daily for 7 days, P22). Isotype is 437 
depicted in grey; CD70 staining in black at diagnosis and in red after treatment with 438 
azacitidine. ΔMFI: MFI staining - MFI isotype. Experiment was performed once for each 439 
patient depicted. (c) Fold change ΔMFI CD70 (Decitabine, 20 mg/kg, daily for 5 days (D (5)) 440 
vs. diagnosis; A (7) vs. diagnosis (AML is depicted as open symbols, azacitidine (A) in red 441 
and decitabine (D) in blue) on lin-CD90-CD34+CD38- AML LSC and lymphocytes. (n=3 and 442 
6 AML patients for A and D, respectively). Significance was determined using a two-sided 443 
paired t-test. (d) Correlation of methylation state at the SP-1 binding site of the CD70 444 
promoter in lin-CD90-CD34+CD38-AML LSCs vs. CD70 protein expression (ΔMFI CD70) in 445 
newly diagnosed AML patients (n=10). ΔMFI: MFI staining - MFI isotype. The correlation 446 
coefficient r was determined using a Pearson correlation. Significance was determined using a 447 
two-sided t-test. (e-g) lin-CD90-CD34+ AML cells were cultured in the presence of the HMA 448 
decitabine (e) and decitabine or azacitidine (f, g) in triplicates as described in (a) and (e) 449 
methylation state of the CD70 promoter (n=5 AML patients) , (f) SP-1 and (g) miR-29b 450 
expression was assessed 48h later (n=3 and 6 AML patients for A and D, respectively). Fold 451 
change is indicated as A vs. Veh or D vs. Veh. Significance in (e) was determined using a 452 
two-sided paired t-test. Significances for panel f, g were determined using a two-sided one-453 
sample tests (hypothetical value =1; f, fav: P = 0.01303; int: P = 0.0079; adv: P = 0.0205. g, 454 
fav: P = 0.0133; int: P = 0.0178; adv: P = 0.0127.) (h, i) FACS-purified lin-CD90-455 
CD34+CD38- LSCs from BM of newly diagnosed AML patients were cultured in the presence 456 
or absence of 0.5μM of HMA (AML is depicted as open symbols, azacitidine (A) in red and 457 
decitabine (D) in blue) or αCD70 mAb (αCD70, clone 41D12-D, 10μg/ml) alone or in 458 




containing αCD70 and HMA or both. Colonies and cells were enumerated after 14 days and 460 
re-plated in triplicates in the absence of treatment compounds (i). Sterile DMSO and a control 461 
mAb specific for the F protein of respiratory syncytial virus (palivizumab) were used as mock 462 
treatment. (h) sCD27 levels in supernatants (n=3 AML patients each for A and D). (i) Serial 463 
re-plating experiments for AML LSCs. Data are normalized to Veh control for each plating 464 
(n=3 and 5 AML patients for A and D, respectively). Significance for panels h and i was 465 
determined using One-way-ANOVAs followed by Tukey’s multiple comparison test. (j-o) 466 
5x106 FACS-purified CD45dimSSClo cells from BM of newly diagnosed AML patients 467 
(patient P10 and P25, Supplementary Table 1) were injected intravenously into the tail vein of 468 
sub-lethally irradiated (2.75 cGy) NSG mice. After engraftment (day 32 (P10) and day 97 469 
(P25) after transplantation), mice were randomized to treatment with control mAb and 470 
10mg/kg αCD70 mAb (41D12-D) intraperitoneally (total of 3 injections) or decitabine and 471 
(1.5mg/kg/day) for five consecutive days27 alone or in combination. (P10, n=2 mice/group 472 
and P25, n=4 mice/group). One day after the last treatment, animals were sacrificed and 473 
blood, spleen and BM were analyzed. (j) CD70 expression on huCD45+lin-CD34+CD38- 474 
LSCs. Decitabine treatment is depicted in blue and vehicle treatment in black. Solid lines 475 
represent CD70 staining and dashed lines isotype control stainings on LSCs. ΔMFI: MFI 476 
staining - MFI isotype. Significance was determined using a two-sided Student’s t-test for P25 477 
(P = 0.0015). (k) sCD27 levels in sera of AML PDX mice. Statistics for P25 was determined 478 
using One-way-ANOVAs followed by Tukey’s multiple comparison test. (l) Absolute 479 
numbers of huCD45+lin−CD34+AML cells in the BM. Significance for P25 was determined 480 
using One-way-ANOVAs followed by Tukey’s multiple comparison test. (m) Frequency of 481 
CD38- AML LSCs within huCD45+lin−CD34+ AML cells. Significance was for P25 482 
determined using One-way-ANOVAs followed by Tukey’s multiple comparison test. (n) 483 




P25 determined using One-way-ANOVAs followed by Tukey’s multiple comparison test. (o) 485 
LSC frequencies estimated using ELDA. Whole BM cells at different dilutions (106, 5x105 486 
and 105, Supplementary Table 1) from treated primary AML xenograft mice were 487 
transplanted into sub-lethally irradiated (2.75 cGy) secondary recipients. Engraftment 488 
frequencies of human AML cells in mouse BM was assessed 67 (P10) and 82 (P25) later. A 489 
frequency of >0.1% of human cells (huCD45+CD33+) in the murine BM was rated as positive 490 
engraftment1,28. LSC frequencies were estimated with ELDA software 491 
(http://bioinf.wehi.edu.au/software/elda/) (see Supplementary Table 2) and significant 492 
differences in LSC frequency were calculated by χ2 (for P25: Veh vs αCD70/D: P = 1.23 e-493 
05; D vs. αCD70/D: P = 0.0037; αCD70 vs. CD70/D: P = 0.0167). Data are represented as 494 
mean. Only statistically significant differences are indicated. 495 
  496 
Fig. 2: The ADCC-enhanced αCD70 mAb cusatuzumab has superior efficacy in 497 
reducing LSCs than αCD70 blockade alone. (a) Lin-CD90-CD34+CD38- LSCs (n=5 AML 498 
patients;  P5, P11, P26-P27) and (b) Lin-CD90+CD34+CD38- HSCs from normal control BM 499 
(n=2 controls; ctrl.4, ctrl.5) were cultured in the presence of different αCD70 mAbs 500 
(αCD70=clone 41D12-D and cusatuzumab) alone or in combination with NK cells (derived 501 
from buffy coats of healthy donors) at a ratio of 1:1 in technical triplicates overnight followed 502 
by plating in methylcellulose. Colony formation was assessed after 14 days. Fold change in 503 
colony formation is indicated vs. Veh. Statistics was determined using One-way-ANOVAs 504 
followed by Tukey’s multiple comparison tests (c-f) 5x106 FACS-purified CD45dimSSClo cells 505 
from BM of patient P27 (Supplementary Table 1, Supplementary Fig. 3) were injected 506 
intravenously into sub-lethally irradiated (2.75 cGy) NSG mice. After engraftment (day 43 507 
after transplantation), mice were randomized to treatment with control mAb, 10mg/kg αCD70 508 




combination with 1.5x106 MACS-purified allogenic NK cells derived from buffy coats of 510 
heathy donors (1 injection at day 43; Groups: Veh, NK cells, αCD70, αCD70/NK cells and 511 
cusatuzumab: n=3 mice/group; Group: cusatuzumab/NK cells: n=4 mice). One day after the 512 
last treatment, animals were sacrificed, and spleen and BM were analyzed. (d) Frequency of 513 
human AML cells (CD45+CD33+) in the BM. Statistics was determined using One-way-514 
ANOVA followed by Tukey’s multiple comparison test. (e) Absolute numbers of 515 
huCD45+CD34+CD38- LSCs in the BM. Statistics was determined using One-way-ANOVA 516 
followed by Tukey’s multiple comparison test. (f) Colony formation of human AML cells. 105 517 
BM cells from xenografted AML mice were plated in technical duplicates and AML colonies 518 
were enumerated 14 days later. Statistics was determined using One-way-ANOVA followed 519 
by Tukey’s multiple comparison test. (g) Lin-CD90-CD34+CD38- LSCs (n=2 AML patients; 520 
P11 and P26) were cultured in the presence of NK cells at a ratio of 1:1 and cusatuzumab 521 
alone or in combination with decitabine in technical triplicates overnight followed by plating 522 
in methylcellulose. Colony formation was assessed after 14 days. Fold change in colony 523 
formation is indicated vs. NK cells. (h) Lin-CD90-CD34+CD38+ blasts and lin-CD90-524 
CD34+CD38- LSCs (n=4 AML patients; P10, P25, P32 and P33) were cultured with 525 
decitabine 0.5μM alone or in combination with cusatuzumab (10μg/ml) in the presence and 526 
absence of NK cells at a ratio of 1:1 in technical triplicates. Cell numbers were assessed after 527 
3 days. Fold change in cell numbers per well is indicated vs. vehicle-treated cells. Statistics 528 
was determined using One-way-ANOVA followed by Tukey’s multiple comparison test. (i, j) 529 
lin-CD90-CD34+CD38- LSCs (n=5 AML patients; P8, P10, P25, P32 and P33) were cultured 530 
in the presence and absence of cusatuzumab (10μg/ml) and NK cells (ratio 1:1) in triplicates. 531 
mRNA expression of genes related to differentiation were analyzed by qRT-PCR after 48h 532 
and by Annexin V FACS staining after 72h, respectively. (i) Heatmap of differentiation-533 




and P33). Significance was determined using a two-sided one-sample t-test (hypothetical 535 
value =1).  Data are shown as mean±S.D. Only statistically significant differences are 536 
depicted. 537 
 538 
Fig. 3: Treatment schedule and response. (a) Treatment schedule for untreated AML 539 
patients treated with different concentrations of cusatuzumab and azacitidine. 1, 3, 10, 20 540 
mg/kg cusatuzumab (Cusa) was given i.v. every second week. Azacitidine was administered 541 
s.c at a dose of 75 mg/kg m2 for 7 consecutive days s.c every 4 weeks. (b) SWIMMR plot 542 
illustrating response and outcome of AML patients treated with cusatuzumab in combination 543 
with azacitidine. Adv., adverse risk; AE, adverse event; BR, best hematologic response; CR, 544 
complete remission; CRi, complete remission with incomplete hematologic recovery; EOT, 545 
end of treatment; fav., favorable risk; Int., intermediate risk; PR, partial remission; SD, stable 546 
disease. (c) Pie chart summarizing the treatment responses. CR, complete remission; CRi, 547 
complete remission with incomplete BM recovery; PR, partial remission. (d) Pie chart 548 
summarizing the MRD assessments in BM of CR/CRi patients. MRD status is depicted for 549 
only 9 out of 10 patients in CR/CRi. BM of patient C9 could not be assessed for MRD status 550 
due to short follow-up (Supplementary Table 8). (e) Frequency of BM blasts as determined by 551 
cytomorphology at day -14, C1D1 and BR (n=12 patients). BM blasts for patient C12 at BR 552 
are not depicted as assessment was not possible due to hypocellular BM. Statistics was 553 
determined using a two-sided paired t-test. (f) Representative cytomorphology for patient C2 554 
at day -14, C1D1 and BR. Cytomorphology of all samples was assessed once. Scale bar = 10 555 
μm. Data are represented as mean±S.D. Only statistically significant differences are depicted. 556 
 557 
Fig. 4: Cusatuzumab reduces LSCs in AML patients. (a) CD70 expression on CD34- AML 558 
cells and CD34+ AML LSPCs in the BM of patients from the study cohort and (P, n=8 559 




out 12 patients enrolled in the study was available to run the analysis. (b) Serum sCD27 561 
(sCD27) levels from AML patients at day -14 (AML, n=12 patients) and in sera of aged-562 
matched healthy donors (HD, n=5). Detection limit (DL) of the assay: 0.2 U/ml. Measurement 563 
was performed in technical duplicates. Significance was determined using a two-sided t-test. 564 
(c) Serum sCD27 levels at day -14, C1D1 and BR (n=12 patients per time point). Dotted line 565 
indicates mean sCD27 levels of healthy aged-matched control. Measurement was performed 566 
in duplicates. Significance was determined using a repeated measures One-way ANOVA 567 
followed by a Tukey's multiple comparisons test. (d) Serum sCD27 levels from AML patient 568 
C2 of the study cohort at day -14, at C1D1 and BR measured in technical duplicates. (e) Fold 569 
change in colony formation for selected patients of the study cohort (n=7). Sufficient material 570 
from 7 out 12 patients enrolled in the study was available to run the analysis. Colony assays 571 
were performed in technical triplicates. Significance was determined using a two-sided paired 572 
t-test.  (f) Colony formation at limiting dilution for patient C2 at day-14 and C1D1 in 573 
technical triplicates. (g) LSC frequencies for patient C2 estimated using ELDA. Colony 574 
assays were performed in technical triplicates (n=1 AML patient, C2). A frequency of >0.1% 575 
of human cells (huCD45+CD33+) in the murine BM was rated as positive engraftment1,28. 576 
LSC frequencies were estimated with ELDA software 577 
(http://bioinf.wehi.edu.au/software/elda/). (h) LSC frequencies for all patients with sufficient 578 
cells in BM aspirates in technical triplicates (n=7 AML patients). Only sufficient material 579 
from 7 out 12 patients enrolled in the study was available to run the analysis. Significance was 580 
determined using a two-sided paired t-test.  (i-k) T cell-depleted FACS-purified BM cells 581 
from patient C2 at day-14 and C1D1 were injected at titrated numbers (106, 2,5x105, 105 and 582 
104) into sub-lethally irradiated (2.75 Gy) NSG mice (n=2 mice/ cell number injected). 583 
Engraftment was assessed after 16 weeks in the BM by FACS. Detection limit for positive 584 
engraftment was set as 0.1% human BM cells (CD45+CD33+). (i) Representative FACS plots 585 




experiment are shown. (j) LSC frequencies estimated using ELDA. A frequency of >0.1% of 587 
human cells (huCD45+CD33+) in the murine BM was rated as positive engraftment1,28. LSC 588 
frequencies were estimated with ELDA software (http://bioinf.wehi.edu.au/software/elda/). 589 
(k) Fold change in stem cell frequency. (l) Heatmap. Common differentially regulated genes 590 
after cusatuzumab treatment in LSPCs of patients C8 and C10 identified via scRNA 591 
sequencing. (m) Histogram of GO enrichment analysis of the biological pathways 592 
significantly affected in Lin-CD34+ AML cells after cusatuzumab monotherapy. (n) Fold-593 
change in apoptosis in lin-CD90-CD34+ LSPCs in BM of AML patients at C1D1 versus day- 594 
14 as analyzed by Annexin V FACS staining (n=7 patients). Significance was determined 595 
using a two-sided one-sample t-test (hypothetical value =1). Data are represented as mean. 596 
Only statistically significant differences are indicated. 597 
 598 
Online methods  599 
Detailed information on experimental design and reagents can be found in the Life Sciences 600 
Reporting Summary.  601 
 602 
Animals. NOD/LtSz-scid IL2Rgnull (NSG) mice were purchased from Charles River 603 
(Sulzfeld, Germany). 6-8 weeks old male and female mice were housed under specific 604 
pathogen-free conditions in individually ventilated cages with food and water ad libitum and 605 
were regularly monitored for pathogens. All animals used in the experiments were age- and 606 
sex-matched Randomization of mice into treatment group was performed using GraphPad 607 
software random number generator. Experiments were conducted and analyzed in a non-608 
blinded fashion. Details on repetitions and replicates are indicated in the Fig. legends. 609 
Experiments were approved by the local experimental animal committee of the Canton of 610 





Cell line. MOLM-13 and NOMO-1 cells were specifically purchased from ATCC for this 613 
study. Therefore, the authors performed no additional authentication. The cell line was tested 614 
mycoplasma-free and was grown in FCS-containing medium recommended by ATCC 615 
(https://www.lgcstandards-atcc.org/?geo_country=ch) with GlutaMAX supplemented 100 616 
U/mL penicillin, and 100 μg/mL of streptomycin in a humidified atmosphere of 95% air and 617 
5% CO2 at 37°C.  618 
 619 
Patients samples for preclinical experiments. Peripheral blood samples and BM aspirates 620 
were obtained from untreated AML patients at diagnosis and HMA-treated AML patients at 621 
the University Hospital of Bern, Switzerland between 2014-2017 (Supplementary Table 1). 622 
Informed written consent was collected from all patients involved in the study. Study data 623 
were collected and managed using REDCap electronic data capture tools hosted at the 624 
Department for BioMedical Research29. Diagnostic BM aspirates that were considered normal 625 
according to hematologist and a surgical pathologist were used as controls.  626 
Serum samples from elderly healthy donors (n=5; 69.2 ± 1.8 yrs) and buffy coats from healthy 627 
donors were obtained from the regional blood transfusion service in Bern. Analysis of 628 
samples was approved by the local ethical committee of Bern, Switzerland (KEK 122/14). 629 
 630 
Antibodies, flow cytometry and reagents for treatment. αCD34-APC (cat. 343607, clone 631 
561, 1:80), αCD34-PE (cat. 343603, clone 561, 1:100), αCD38-PE-Cy7 (cat. 303515, clone 632 
HIT2, 1:50), αCD90-PerCP-Cy5.5 (cat. 382113, clone 5E10, 1:100), αCD33-PerCP-Cy5.5 633 
(cat 302413, clone WM53, 1:100), CD45RA-APC-Cy7 (cat. 304151, clone HI100, 1:20), 634 
αCD8a-PerCP-Cy5.5 (cat. 300923, clone HIT8a, 1:100), αCD4-PerCP-Cy5.5 (cat. 344607, 635 




PerCP-Cy5.5 (cat. 103131, clone 30-F11, 1:200), mouse-αCD45-PE-Cy7 (cat. 103113, clone 637 
30-F11, 1:200), Annexin-V-Pacific blue (1:50) were from BioLegend. Lineage-positive cells 638 
were excluded by staining using biotinylated αCD2 (cat. 300203, clone RPA2.10, 1:100), 639 
αCD3 (cat. 317319, clone OKT3, 1:100), aCD14 (cat. 325623, clone HCD14, 1:100), αCD16 640 
(cat. 302003, clone 3G8, 1:100), αCD19 (cat. 302203, clone HIB19, 1:100), αCD56 (cat. 641 
318319, clone HCD56, 1:100) and αCD235 (cat. 306617, clone HIR2, 1:100) (BioLegend), 642 
followed by a second step using streptavidin-FITC (BD Pharmingen, 1:3000). αCD70-PE 643 
(cat. 555835, clone KI-24, 1:10) and corresponding isotype control mAb were from BD 644 
Pharmingen. Viability dye eFluor450 was from eBiosciences (1:1000). αCD45-V-500C (cat. 645 
56077; clone 2DI, 1:50) was from BD Pharmingen. 646 
Flow cytometric analysis on whole BM was performed following red blood cell (RBC) lysis. 647 
Samples were analyzed on a BD Fortessa and sorting procedures were performed using a BD 648 
FACS Aria III (BD Pharmingen). Data were collected using FACSDiva software (BD 649 
Pharmingen) analyzed using FlowJo software (Treestar). Effective separation after FACS-650 
sorting was assessed by re-analyzing a fraction of the sorted samples by flow-cytometry 651 
analysis (purity after FACS-sorting: 95.3 ± 1.3%). Human αCD70 mAb (41D12-D) 652 
specifically blocks the CD70/CD27-interaction with deficiency in effector functions by 653 
E233P/L234V/L235A amino acid substitutions in the CH2 domain of the parental clone 654 
41D12-D18,19, cusatuzumab and pavilizumab (Synagis®, mock treatment) were from argenx. 655 
 656 
RNA isolation and qRT-PCR. For qRT-PCR, total RNA was extracted using the RNeasy 657 
Mini Kit (Qiagen). Complementary DNA synthesis was performed using the High Capacity 658 
cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression analysis was 659 
performed using self-designed primers for CD70 (FW, TGCTTTGGTCCCATTGGTC; RV, 660 




GGACTGATCGTGCTTCGTG), CEBPB (FW, TTTCGAAGTTGATGCAATCGG; RV, 662 
AAACATCAACAGCAACAAGCC), ID1 (FW: TGTTACTCACGCCTCAAGGA; RV: 663 
CTGAAGGTCCCTGATGTAGTC), RUNX1 (FW: GCTTCACTCTGACCATCACTG; RV: 664 
TGCCGATGTCTTCGAGGT),  SPI1 (FW: CCTCAGCCATCAGAAGACCT; RV: 665 
CAGTAATGGTCGCTATGGCTC), SP-1 (FW, AGAGGCCATTTATGTGTACCTG; RV, 666 
AGGGCAGGCAAATTTCTTCTC),  and GAPDH (FW, 667 
TCATTTCCTGGTATGACAACGA; RV, CTTCCTCTTGTGCTCTTGCTG) using SYBR 668 
Green Reaction. qRT-PCR reactions were performed in duplicates including non-template 669 
controls using an ABI Prism 7500 Sequence Detection System (Applied Biosystems). 670 
Relative quantification of gene expression was normalized against a reference gene (GAPDH) 671 
and calculated as an exponent of 2 (2ΔCt). 672 
 673 
MicroRNA analysis. Total RNA was extracted using the RNeasy Micro Kit (Qiagen) and 674 
cDNA synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied 675 
Biosystems). MicroRNA concentrations were measured using TaqMan miRNA assays for 676 
miR-29b, or RNU48 (Applied Biosystems), and qRT-PCR results were normalized to RNU48 677 
expression. 678 
 679 
Liquid cultures. 1x105 FACS-purified CD34+CD38- LSCs from BM of AML patients and or 680 
HSCs from normal control BM (ctrl., Supplementary Table 1) were cultured in StemSpan 681 
SFEM medium (Stem Cell Technologies) supplemented with human cytokines (StemSpan 682 
CC100; Stem Cell Technologies) in the presence or absence of 10 mg/ml αCD70 mAb or 0.5 683 
μM decitabine or azacitidine alone or in combination in 96-well plates at 37°C and 5% CO2. 684 
Numbers of viable cells were assessed by trypan blue staining or viability dye staining. CD70 685 





Colony assays. Colony assays of FACS-purified CD34+CD38- LSCs from the peripheral 688 
blood or BM of newly diagnosed AML patients or normal control BM (ctrl., Supplementary 689 
Table 1) were performed as previously described with slight modifications30. Briefly, 1×103 690 
CD34+CD38- cells were cultured overnight in 96-well plates at 37°C and 5% CO2 in 691 
StemSpan SFEM medium in the presence or absence of 10 mg/ml αCD70 mAb or 0.5 μM 692 
decitabine or azacitidine alone or in combination followed by plating into MethoCult H4435 693 
enriched medium (methylcellulose, STEMCELL Technologies). αCD70 and HMA were 694 
added in the first cultures but not during re-plating. Sterile DMSO and a control mAb specific 695 
for the F protein of respiratory syncytial virus (palivizumab) were used as mock treatment. 696 
Colonies and cells were enumerated after 14 days (≥30 cells/colony). For serial re-plating 697 
experiments, 104 cells were collected from preceding colony assays and were re-plated in 698 
methylcellulose without further addition of mAb or HMA. Colonies were enumerated 14 days 699 
later. 700 
 701 
Murine patient-derived xenograft AML model and limiting dilution experiments. 702 
Patient-derived xenotransplantation experiments were performed as previously described11. 703 
NSG mice were sub-lethally irradiated (2.75 Gy) on the day before injection. 5×106 FACS-704 
purified CD45dimSSClo from BM of newly diagnosed AML patients (patient P10, P25 and 705 
P27, Supplementary Table 1) were injected intravenously into the tail vein. The CD34+ cell 706 
frequencies for PDX of P10: 90.4±0.2, for PDX 25: 5.8±0.8, and for PDX 27: 81,8±1.0.   707 
Five weeks (P10), 12 (P25) and 6 weeks (P27) after transplantation, mice were randomized 708 
using GraphPad software random number generator into the different treatment groups as 709 
specified in the respective figure legends. 710 
For the analysis of BM in xenografted AML mice, the immunophenotype of LSCs was 711 




For limiting dilution assays, whole BM cells from treated primary AML xenograft mice or 713 
AML study patients at diagnosis and after cusatuzumab monotherapy were transplanted at 714 
titrated numbers into sub-lethally irradiated (2.75 Gy) secondary recipients and engraftment in 715 
blood, spleen and BM was assessed at time points indicated in figure legends. A frequency of 716 
>0.1% of human cells (huCD45+CD33+) in the murine BM was rated as positive engraftment. 717 
To study LSC frequencies for patient C2 at day-14 and C1D1 in vivo, FACS-purified T-cell 718 
depleted BM cells were injected at titrated numbers into sub-lethally irradiated (2.75 Gy) 719 
secondary recipients. Engraftment was assessed after 16 weeks in the BM by FACS. A 720 
frequency of >0.1% of human cells (huCD45+CD33+) in the murine BM was rated as positive 721 
engraftment. 722 
 723 
sCD27 measurements 724 
sCD27 levels in cell supernatants and in serum of PDX mice were analyzed by ELISA as 725 
previously described in 11. Soluble CD27 (sCD27) in serum from patients enrolled in the 726 
clinical trial was measured in duplicates using the CD27 (Soluble) Human Instant ELISA™ 727 
Kit (Invitrogen). Detection limit of the assay was 0.2 U/ml.  728 
 729 
DNA methylation analysis of the CD70 promoter. The methylation of the SP-1 binding site 730 
at the CD70 promoter was analyzed in FACS-purified lin-CD90-CD34+CD38- AML LSCs and 731 
lin-CD90+CD34+CD38- HSCs from newly diagnosed AML patients and healthy donors (HD) 732 
as well as from lin-CD90-CD34+ AML cells which were treated with vehicle or decitabine at 733 
0.5μM overnight in 3 independent replicates per condition.  734 
Bisulfite conversion of isolated DNA of cells was assessed using the Epitect® Bisulfite Kit 735 
(Qiagen) according to the manufacturer’s protocol. The promoter region covering binding 736 




forward primer 5’- GAGAGGGGTATACGAATATTTGG-3’; reverse primer 5’- 738 
ACCGCTACCAATCTAAAAATCC -3’. For the amplification of bisulfite-treated genomic 739 
DNA (gDNA), the following PCR conditions were used: 1x 95°C for 10min; 40x 95°C for 740 
30s, 56°C for 30s, 72°C for 1min; 1x 72°C for 5min. The PCR cocktail consisted of 3μl of 741 
DNA (of at least 10ng/μl DNA for a final concentration of 3ng/μl per reaction) in a 25μl total 742 
volume using 1µl of each primer (10µM), 200μM dNTPs, 0.2U hot start Taq DNA 743 
polymerase, 2µl Q-solution 5x (Qiagen), 1.5mM MgCl2 and the buffer supplied with the 744 
enzyme. Subsequent nested PCR was performed with the following primers: forward primer 745 
5’ -GAGTATTTTTAATTTTTGGATGTTTGTTG-3’ and reverse primer 5’- 746 
ACAATTACCAAAATACAAACAATAACC-3’, using the same PCR conditions as 747 
described above for bisulfite sequencing. The amplified promoter region was gel-purified and 748 
subjected to fluorescent Sanger sequencing. The relative quantification of the methylated 749 
allele (C) versus the unmethylated allele (T) was assessed using the QSVAnalyser software 750 
(University of Leeds)33. 751 
 752 
Determination of synergy. Synergy between compounds was quantified using the Chou-753 
Talalay method22. For synergy studies, we calculated the % reduction of cell numbers after 754 
drug treatments compared to vehicle-treated cells. We determined the half-maximal inhibitory 755 
concentrations (IC50) of cusatuzumab and decitabine in the presence of NK cells (derived 756 
from buffy coats of healthy donors) and treated MOLM-13 cells with titrated concentrations 757 
of the compounds, below, or above the IC50. Dose effect analysis, the dose response values 758 
IC50, the slope (m) and the correlation coefficient (r) for the single treatments, as well as the 759 
combination index (CI) that reflects the extent of synergy or antagonism for two drugs were 760 





Single-cell RNA sequencing (scRNA-seq) workflow and analysis  763 
Barcoded cDNA from of at least 977 lin-CD34+ cells from patients C8 and C10 was prepared 764 
using the Chromium Single Cell 3′ Library (v2 Chemistry) & Gel Bead Kit on a Chromium 765 
Controller according to the manufacturer’s recommendations (10XGenomics). The barcoded 766 
cDNA was further processed into scRNA-seq libraries and sequenced on a NovaSeq 6000 767 
instrument using NovaSeq Control Software v1.6 (Illumina). Libraries were sequenced with 768 
100 cycle S1 flow cell kits using the following paired-end configuration: 26 bp Read 1, 91 bp 769 
Read 2. 770 
For post-processing of the samples and alignment of the cDNA reads to the human reference 771 
transcriptome (GRCh38), the CellRanger package (v2.1.1, 10X Genomics) was employed34. 772 
This process allocates a unique molecular identifier (UMI, transcript) expression matrix to 773 
only those single cells containing a cell-barcode (filtered feature-barcode matrix). The 774 
expression matrix of each single cell was then normalized by the “cellranger aggr” function 775 
from the CellRanger package. This resulted in the identification of 4,883 cell-barcodes with a 776 
median UMI per cell of 9972 and median expression of 2400 genes per cell for patient C8 and 777 
2266 cell-barcodes with a median UMI per cell of 9138 and median expression of 2215 genes 778 
per cell for patient C10. Subsequently, the Seurat package (v2.3.4) was used for quality 779 
control (filtering), graph-based clustering, visualization and differential gene expression 780 
analysis for on single cell level35. Single cells identified by the Seurat package as outliers 781 
(>3500 expressed genes) and cells that showed a high level (>5%) of reads that aligned to the 782 
mitochondrial genome were removed36. To discriminate between malignant and healthy single 783 
cells in our samples, we took advantage of the molecular mutations identified at diagnosis in 784 
patients C8 and C10 and performed a data crushing approach. Single cells with a log2 gene 785 
expression of ≥10-5 and <10-5 of the respective marker(s) were considered as healthy cells and 786 
malignant cells, respectively. Unsupervised cell-clustering and differential genes expression 787 




the Seurat package and the Seurat “findMarker” function, respectively. All figures and tables 789 
related to the scRNA-seq analysis were generated based on the filtered malignant cells. 790 
 791 
Patients and study design. Argx-110-1601 was a phase 1/2, open-label, dose-escalating 792 
study (n=12 patients) with a proof of concept cohort (n=26 patients) to evaluate the safety, 793 
tolerability, and efficacy of ARGX-110 in combination with azacytidine in subjects with 794 
newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome 795 
(MDS) (NCT03030612). This manuscript reports the results of the dose-escalation part of the 796 
phase 1/2 study (n=12 patients). The dose-escalation part used a 3 + 3 design to establish the 797 
maximum-tolerated dose of cusatuzumab in combination with azacitidine. Cusatuzumab was 798 
administered intravenously every 2 weeks (first dose at day -14, all further applications on 799 
days 3 and 17 of all therapy cycles) at 1, 3, 10 and 20 mg/kg b.w. in combination with 800 
standard doses of subcutaneous azacitidine of 75 mg/m2 given at days 1 to 7 every 28 days. 801 
Main inclusion criteria were: untreated AML ≥ 20% blasts, age ≥ 18 years, expected life 802 
expectancy ≥ 3 months, ECOG performance status of 0, 1, or 2. Main exclusion criteria were: 803 
Prior or concurrent malignancy, any previous cancer chemo- or radiotherapy, abnormal organ 804 
function (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 x 805 
upper limit of normal (ULN) or in case of liver infiltration by AML, AST and/or ALT > 5 x 806 
ULN; Alkaline phosphatase (AP) > 2.5 x ULN or in case of liver infiltration by AML, AP > 5 807 
x ULN; Serum (total) bilirubin > 1.5 x ULN or in case of liver infiltration by AML, serum 808 
(total) bilirubin > 5 x ULN; Serum creatinine > 2.5 x ULN or GFR (MDRD) of < 40 mL/min 809 
for patients with creatinine levels above the normal limit); use of immune-suppressive agents 810 
for the past 4 weeks. The primary objective of the phase 1 was to determine the MTD of 811 
cusatuzumab (formerly ARGX-110) and/or the recommended phase 2 dose (RP2D) in 812 
combination with a standard dose of azacitidine. The secondary objectives involved 813 




pharmacodynamics and preliminary efficacy of multiple ascending intravenous doses of 815 
cusatuzumab in combination with standard doses of azacitidine. 816 
The trial (EudraCT number 2016-002151-17) was sponsored by argenx, (Belgium) and 817 
conducted in compliance with the Declaration of Helsinki and the International Conference on 818 
Harmonization Good Clinical Practices Guidelines. The clinical study protocol and its 819 
amendments, informed consent documents, and any other appropriate study-related 820 
documents were reviewed and approved by the applicable ethics committee of Bern, 821 
Switzerland, and the national regulatory authorities Swissmedic in Bern, Switzerland. Patients 822 
in the phase 1 part of the trial were enrolled between January 2017 and March 2018 at the 823 
Inselspital, Bern University Hospital and the University Hospital Zürich. 824 
Samples were collected at diagnosis (day -14) and for response assessments of cusatuzumab 825 
monotherapy (C1D1) and at regular intervals during the trial. Pharmacodynamics as well as 826 
pharmacokinetic samples were collected during monotherapy as well as combination therapy. 827 
The intermediate cut-off for this report in the ongoing study was February 18th  2019. 828 
 829 
Response criteria  830 
The hematologic remission status was assessed according to the criteria of the International 831 
Working Group15,37. MRD was evaluated by multi-parameter flow cytometry according to the 832 
criteria of the European Leukemia Net (ELN). The detection of at least 0.1% (>10-3) of cells 833 
with a leukemia-associated immunophenotype was considered as positive MRD result38.  834 
 835 
Cytogenetic and mutation analysis 836 
Chromosome banding analysis from bone marrow was done according to standard procedures 837 
with a minimum of 20 metaphases being required for a valid report. Fluorescence in situ 838 
hybridization (FISH) and/or array comparative hybridization (aCGH) were added if needed 839 




Mutations detected at diagnosis in the 12 patients in this study (e.g. CEBPA, EZH2, RUNX1, 841 
SH2B3, ZRSR2, NPM1; see Supplementary Table 3) were determined by NGS.  842 
 843 
Statistical analysis 844 
Statistical analysis was performed using GraphPad Prism® software v7.0 (GraphPad). Bars 845 
and error bars indicate means and standard deviations if not otherwise specified in Fig. 846 
legends. All statistical tests were two-sided and P values ≤ 0.05 (95% confidence interval) 847 
were considered statistically significant. Normality was measured using the D'Agostino & 848 
Pearson normality test for all experiments with n≥8. Correlations were performed using a 849 
Pearson correlation coefficient. Data were analyzed using one-sample test (hypothetical value 850 
=1); Student’s t-test, paired t-test, one-way ANOVA followed by Tukey’s multiple 851 
comparison test, repeated measure one-way ANOVA followed by Tukey’s multiple 852 
comparison test.  The test applied to determine significances is specified in detail in the 853 
corresponding figure legend. LSC frequencies with 95% confidence intervals (CI) were 854 
estimated with Extreme Limiting Dilution Analysis software 855 
(http://bioinf.wehi.edu.au/software/elda/) and significant differences in LSC frequency were 856 
calculated by χ2 test in limiting dilution assays according to21. The statistical analysis of 857 
differentially expressed genes in CD34+ AML cells before and after cusatuzumab treatment 858 
was performed using a Wilcoxon rank sum test followed by a P value adjustment using 859 
Bonferroni correction. 860 
 861 
Data availability statement 862 
Patient-related clinical data sets in the paper were generated during and analyzed as part of the 863 
part of a multicenter clinical trial (NCT03030612). The data sets are not publicly available  864 




data lock and completion of trial or on reasonable request. 866 
All RNA raw data, the analyzed sequencing data can be found at the GEO database and are 867 
available via accession number GSE147989 (single cell RNA-seq). 868 
All other data that support the findings of the study are available from the corresponding 869 
author upon request.  870 
 871 
Code availability statement 872 
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